3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
6
Radiotherapy
5
olaparib
3
exemestane
3
Paclitaxel
3
Letrozole
3
Itraconazole
3
Gemcitabine
3
Fulvestrant
3
Carboplatin
3
Blood Specimen Collection
3
palbociclib
2
fludarabine phosphate
2
eribulin
2
avelumab
2
abemaciclib
2
Therapeutics
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Mastectomy
2
Flow Cytometry
2
Filgrastim
2
Exercise
2
Everolimus
2
Etoposide
2
Dasatinib
2
Cetuximab
2
Carmustine
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
tinostamustine
×
Breast
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts